Kibow Biotech Inc. was present at the 2015 Kidney Week Conference to showcase its “Enteric Dialysis or Uremic Toxin Reduction Technology” for the treatment of patients with chronic kidney disease (CKD). The annual conference is organized by the American Society of Nephrology (ASN), and this year took place at the San Diego Convention Center.
For Kibow Biotech’s 10th year at the conference, the company exhibited its technology based on the modulation of the Gut Microbiome with a dietary supplement product created with specific strains of Probiotics and selected Prebiotics. The purpose is to induce the modulation and stabilization of the gut microbiome to address kidney failure problems. During the conference, the company posted its scientific poster abstract presentations, which included cumulative preliminary data from three different pilot/observational scientific human clinical trials and pharma like validation of its dietary supplement Renadyl.
The Uremic Toxin Reduction Technology is designed to fight the diffusion of uremic toxins into the bowel as result of failing kidney function. Renadyl, the probiotic and prebiotic dietary supplement patented by the company, is able to target the buildup of uremic toxins in the body while helping reduce these toxins, increasing healthy kidney function. The product is commercialized online and the US Food and Drug Administration (FDA) has granted it the Generally Recognized as Safe (GRAS) status.
Additionally, Kibow is working on the possibility of advancing the supplement and commercializing it with a prescription drug status, for which the company will need to obtain the Investigational New Drug (IND) designation as well as several additional human Randomized Controlled Trials (RCT) in the forthcoming years in the US and possibly abroad in order to receive FDA approval. If approved, the supplement is expected to gain greater acceptance among healthcare professionals and patients.
In addition to the 2015 ASN Kidney Week, the company has already presented its work at the 3rd World Congress on Targeting Gut Microbiota towards clinical revolution which took place at the Pasteur Institute in Paris from Oct 21-23, where Dr. Natarajan Ranganathan gave an oral presentation on the same “Enteric Dialysis Concept” and Gut-Kidney connection.